Tags

Type your tag names separated by a space and hit enter

NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome.
Yonsei Med J. 2015 Jan; 56(1):204-11.YM

Abstract

PURPOSE

To determine whether levels of nerve growth factor (NGF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to objectively assess overactive bladder syndrome (OAB) treatment outcome and to evaluate the effects of fixed-dose fesoterodine on OAB symptoms.

MATERIALS AND METHODS

This study included 124 participants (62 patients with OAB and 62 controls) in Severance Hospital between 2010 and 2012. In patients with OAB, 4 mg fesoterodine was administered once daily. Repeated evaluations of putative biomarker levels, urine creatinine (Cr) levels, and questionnaire responses, including the Overactive Bladder Symptom Score (OABSS) and the Overactive Bladder Questionnaire (OAB q), were performed from baseline to 16 weeks.

RESULTS

Urinary levels of NGF/Cr (OAB: 1.13±0.9 pg/mg; control: 0.5±0.29 pg/mg) and HB-EGF/Cr (OAB: 8.73±6.55 pg/mg; control: 4.45±2.93 pg/mg) were significantly higher in subjects with OAB than in controls (p<0.001). After 16 weeks of fixed-dose fesoterodine treatment, urinary NGF/Cr levels (baseline: 1.13±0.08 pg/mg; 16 weeks: 0.60±0.4 pg/mg; p=0.02) and HB-EGF/Cr levels significantly decreased (baseline: 8.73±6.55 pg/mg; 16 weeks: 4.72±2.69 pg/mg; p=0.03, respectively). Both the OABSS and OAB q scores improved (p<0.001). However, there were no a statistically significant correlations between these urinary markers and symptomatic scores.

CONCLUSION

Urinary levels of NGF and HB-EGF may be potential biomarkers for evaluating outcome of OAB treatment. Fixed-dose fesoterodine improved OAB symptoms. Future studies are needed to further examine the significance of urinary NGF and HB-EGF levels as therapeutic markers for OAB.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea.Department of Obstetrics and Gynecology, Institute of Women's Life Medical Science, Yonsei University College of Medicine, Seoul, Korea. swbai@yuhs.ac.

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25510766

Citation

Kim, Soo Rim, et al. "NGF and HB-EGF: Potential Biomarkers That Reflect the Effects of Fesoterodine in Patients With Overactive Bladder Syndrome." Yonsei Medical Journal, vol. 56, no. 1, 2015, pp. 204-11.
Kim SR, Moon YJ, Kim SK, et al. NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei Med J. 2015;56(1):204-11.
Kim, S. R., Moon, Y. J., Kim, S. K., & Bai, S. W. (2015). NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. Yonsei Medical Journal, 56(1), 204-11. https://doi.org/10.3349/ymj.2015.56.1.204
Kim SR, et al. NGF and HB-EGF: Potential Biomarkers That Reflect the Effects of Fesoterodine in Patients With Overactive Bladder Syndrome. Yonsei Med J. 2015;56(1):204-11. PubMed PMID: 25510766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - NGF and HB-EGF: potential biomarkers that reflect the effects of fesoterodine in patients with overactive bladder syndrome. AU - Kim,Soo Rim, AU - Moon,Yeo Jung, AU - Kim,Sei Kwang, AU - Bai,Sang Wook, PY - 2014/12/17/entrez PY - 2014/12/17/pubmed PY - 2015/6/13/medline KW - Heparin-binding EGF-like growth factor KW - nerve growth factor KW - overactive bladder KW - questionnaire KW - urinary biomarkers SP - 204 EP - 11 JF - Yonsei medical journal JO - Yonsei Med J VL - 56 IS - 1 N2 - PURPOSE: To determine whether levels of nerve growth factor (NGF) and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to objectively assess overactive bladder syndrome (OAB) treatment outcome and to evaluate the effects of fixed-dose fesoterodine on OAB symptoms. MATERIALS AND METHODS: This study included 124 participants (62 patients with OAB and 62 controls) in Severance Hospital between 2010 and 2012. In patients with OAB, 4 mg fesoterodine was administered once daily. Repeated evaluations of putative biomarker levels, urine creatinine (Cr) levels, and questionnaire responses, including the Overactive Bladder Symptom Score (OABSS) and the Overactive Bladder Questionnaire (OAB q), were performed from baseline to 16 weeks. RESULTS: Urinary levels of NGF/Cr (OAB: 1.13±0.9 pg/mg; control: 0.5±0.29 pg/mg) and HB-EGF/Cr (OAB: 8.73±6.55 pg/mg; control: 4.45±2.93 pg/mg) were significantly higher in subjects with OAB than in controls (p<0.001). After 16 weeks of fixed-dose fesoterodine treatment, urinary NGF/Cr levels (baseline: 1.13±0.08 pg/mg; 16 weeks: 0.60±0.4 pg/mg; p=0.02) and HB-EGF/Cr levels significantly decreased (baseline: 8.73±6.55 pg/mg; 16 weeks: 4.72±2.69 pg/mg; p=0.03, respectively). Both the OABSS and OAB q scores improved (p<0.001). However, there were no a statistically significant correlations between these urinary markers and symptomatic scores. CONCLUSION: Urinary levels of NGF and HB-EGF may be potential biomarkers for evaluating outcome of OAB treatment. Fixed-dose fesoterodine improved OAB symptoms. Future studies are needed to further examine the significance of urinary NGF and HB-EGF levels as therapeutic markers for OAB. SN - 1976-2437 UR - https://www.unboundmedicine.com/medline/citation/25510766/NGF_and_HB_EGF:_potential_biomarkers_that_reflect_the_effects_of_fesoterodine_in_patients_with_overactive_bladder_syndrome_ L2 - https://www.eymj.org/DOIx.php?id=10.3349/ymj.2015.56.1.204 DB - PRIME DP - Unbound Medicine ER -